Pfizer (NYSE:PFE) Stock Price Expected to Rise, Guggenheim Analyst Says

Pfizer (NYSE:PFE) had its price objective hoisted by stock analysts at Guggenheim from $31.00 to $33.00 in a research report issued on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Guggenheim‘s target price indicates a potential upside of 6.15% from the stock’s previous close.

PFE has been the subject of a number of other research reports. Citigroup upped their price objective on shares of Pfizer from $27.00 to $30.00 and gave the stock a “neutral” rating in a research report on Wednesday. HSBC lifted their price target on Pfizer from $28.00 to $30.00 and gave the company a “hold” rating in a research note on Thursday, September 10th. UBS Group increased their price target on Pfizer from $27.00 to $30.00 and gave the stock a “neutral” rating in a research report on Wednesday. BMO Capital Markets dropped their price objective on Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a report on Monday, July 13th. Finally, Scotiabank boosted their price objective on Pfizer from $33.00 to $35.00 and gave the company a “sector outperform” rating in a research report on Wednesday. Five research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $29.94.

Pfizer Stock Performance

PFE traded up $0.30 during midday trading on Thursday, hitting $31.09. 11,381,664 shares of the company were exchanged, compared to its average volume of 39,689,750. The company’s 50 day simple moving average is $28.69 and its 200 day simple moving average is $26.86. The firm has a market capitalization of $177.20 billion, a price-to-earnings ratio of 44.37, a price-to-earnings-growth ratio of 2.04 and a beta of 0.31. Pfizer has a 1-year low of $23.62 and a 1-year high of $31.44. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.13. Pfizer had a return on equity of 19.98% and a net margin of 6.34%. The firm had revenue of $16.58 billion for the quarter, compared to the consensus estimate of $15.85 billion. During the same quarter in the prior year, the business earned $0.87 earnings per share. The company’s revenue was down .4% compared to the same quarter last year. As a group, sell-side analysts predict that Pfizer will post 2.94 earnings per share for the current year.

Hedge Funds Weigh In On Pfizer

A number of institutional investors have recently bought and sold shares of PFE. BlackRock Inc. raised its stake in Pfizer by 6.3% during the second quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock worth $12,754,464,000 after acquiring an additional 31,412,883 shares during the period. State Street Corp boosted its stake in Pfizer by 1.8% in the second quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company’s stock valued at $7,394,749,000 after acquiring an additional 5,501,032 shares during the period. Bank of New York Mellon Corp boosted its stake in Pfizer by 7.4% in the second quarter. Bank of New York Mellon Corp now owns 57,879,546 shares of the biopharmaceutical company’s stock valued at $1,393,739,000 after acquiring an additional 3,999,646 shares during the period. Bank of America Corp DE bought a new position in shares of Pfizer during the second quarter valued at approximately $1,049,602,000. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Pfizer by 0.8% during the first quarter. Dimensional Fund Advisors LP now owns 36,422,799 shares of the biopharmaceutical company’s stock valued at $1,022,606,000 after purchasing an additional 293,029 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer beat Q3 earnings and revenue expectations and raised its 2026 forecast to $62–$64 billion in revenue and adjusted EPS of $2.95–$3.05. Launched and acquired products grew 32% operationally, while non-COVID products rose 7%. Article: Pfizer: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Scotiabank raised its price target to $35 and reiterated “sector outperform,” adding to the positive outlook surrounding the results. Scotiabank analyst recommendations
• Positive Sentiment: A recent TipRanks article described Pfizer’s dividend as well-covered and the stock’s valuation as modest, potentially appealing to income-focused investors. Article: Pfizer Stock Looks Attractive for Income Investors
• Neutral Sentiment: Analyst views remain mixed: RBC raised its target to $28 and UBS and Citi to $30, but all maintained neutral or sector-perform ratings—targets below the price cited in the reports. RBC analyst recommendations
• Negative Sentiment: Revenue was roughly flat as COVID product sales continued to decline, and margin pressure remains a concern. Pfizer must sustain growth in newer products and deliver on cost savings and pipeline milestones to make the raised outlook durable. Article: Pfizer Just Raised Guidance. The Bigger Test Comes Next

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.